Arcus annual meeting elects directors, ratifies E&Y, approves say-on-pay; board revises director comp

Arcus Biosciences, Inc.

All four Class I director nominees elected with >86M votes each (broker non-votes ~8.6M).
Ernst & Young ratified as auditor for FY2025 with 96.8M votes for (96.3% of votes cast).
Advisory 'say-on-pay' approved with 84.8M for (93.9% of votes cast excluding abstentions).
Board revised Non-Employee Director Compensation Program: $50k cash retainer, $750k initial equity, $400k annual equity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.